Skip to content

Discontinued — last reported Q4 '25

CapEx at other companies

Eli Lilly logo
Eli LillyLLY
$2.33B+54.0%
Merck & Co. logo
Merck & Co.MRK
$991M-25.4%
Amgen logo
AmgenAMGN
$712M+73.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$230.6M+0.6%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$997K+261%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$4.66M+141%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+102%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The official record: KLRS’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's capex?
KLRS (KLRS) reported capex of $17K in Q4 2025.
What does capex mean?
Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.